Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular Prevention by Ridker, Paul M.
 
Hyperlipidemia as an Instigator of Inflammation: Inaugurating New
Approaches to Vascular Prevention
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ridker, Paul M. 2012. Hyperlipidemia as an instigator of
inflammation: Inaugurating new approaches to vascular
prevention. Journal of the American Heart Association 1(1): 3-5.
Published Version doi:10.1161/JAHA.112.000497
Accessed February 19, 2015 11:54:01 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10581272
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAHyperlipidemia as an Instigator of Inﬂammation: Inaugurating New
Approaches to Vascular Prevention
Paul M Ridker, MD
F
or much of the past quarter century, 2 broadly compet-
ingscientiﬁcviewshavedominatedtranslationalresearch
concerning atherogenesis and atherothrombosis. On one side
has been a predominantly lipid-centric view in which low-
density lipoprotein (LDL) cholesterol, a proven causal factor
in atherosclerosis, has been viewed as the major if not sole
determinant of disease initiation and progression. Pioneering
descriptions of the role played by the LDL receptor in human
disease and the remarkable success of statin therapy provide
Article on p 27
emblematic support for this scientiﬁc viewpoint and are
milestones in the history of cardiovascular medicine.1 Ongo-
ing research into agents that reduce proprotein convertase
subtilisin/kexin type 9 (PCSK9) activity2 or that inhibit the in-
testinal Niemann-Pick C1-like protein 1 (NPC1L1) cholesterol
transporter3 represent current expressions of the established
view that ever lower levels of LDL cholesterol are likely to be
beneﬁcial, and that pharmacologic inhibition of cholesterol on
top of statin therapy might again transform medical practice.
However, there are paradoxes in the LDL literature that
have long puzzled investigators including observations that
LDL cholesterol is only a modest predictor of vascular risk
in the general population; that most myocardial infarction
and stroke events occur among those with relatively low
LDL cholesterol levels; that not all agents that reduce LDL
cholesterol reduce vascular events; and that the relative risk
reductions associated with statin therapy occur within weeks
of drug initiation and are fully independent of the underlying
level of LDL cholesterol.
These paradoxes are commonly cited to support an al-
ternative view of atherothrombosis based fundamentally on
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the vascular biology of inﬂammation. Rather than viewing
atherosclerosis solely as a lipid deposition disorder within a
passive arterial wall, the inﬂammatory model of atherogene-
sis and atherothrombosis proposes that critical components
of the innate and adaptive immune systems contribute heav-
ily to atherogenesis and thus that alterations of immunity may
havetherapeuticpotential.4 Withregardtothe“fastandblunt”
innate immune response, multiple cells involved in atheroscle-
rosis express pattern recognition receptors that can alter in-
ﬂammatory signaling, and recent work suggests crucial roles
formonocyte/macrophagelinesaswellasmastcellsinhuman
atherogenesis. With regard to the “slow but speciﬁc” adaptive
immune response based on antigen presentation and biologic
memory, abundant evidence has accrued implicating several
speciﬁc types of antigen recognizing T cells, antibody secret-
ing B lymphocytes, and antigen presenting dendritic cells in all
stages of the atherothrombotic process.
At times, the above world views have appeared to be in
competition. However, for most investigators within the trans-
lational research community, hypotheses characterized as
strictly “lipid driven” or strictly “inﬂammation driven” present
a false dichotomy. Few if any supporters of the inﬂammation
hypothesis do not fully endorse the fundamental role of LDL
cholesterol in atherogenesis, just as few if any supporters of
the LDL-centric hypothesis do not recognize the pro- and anti-
inﬂammatory effects that different lipid fractions have on vas-
cular function. In this regard, modiﬁed lipoproteins are known
to interact with scavenger receptors of the innate immune
system, and direct binding of oxidized LDL to CD36 and of
apolipoprotein CIII to toll-like receptor 2 is well described.5
In my own research group, we have long looked at the
“lipid” and “inﬂammation” hypotheses as closely interrelated
because clinical data supporting inﬂammation largely parallel
thosesupportingLDLcholesterol.Asexamples,themagnitude
of risk associated with each standard deviation increase in the
inﬂammatory biomarker C-reactive protein (CRP) is remark-
ably similar to that of LDL cholesterol, and both contribute
independently toward improved vascular risk prediction.6 Fur-
ther,statinssigniﬁcantlyreducebothLDLcholesterolandCRP,
and reductions in each parameter have consistently proven to
be important as determinants of overall statin efﬁcacy.7,8 In
the recently completed JUPITER trial, statin therapy was highly
effectiveatloweringvasculareventratesinprimaryprevention
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evenamongmenandwomenwithlevelsofLDLcholesterolwell
below current treatment thresholds, and this beneﬁt occurred
concomitantly with large reductions in both LDL cholesterol
and CRP.9 An appealing view of statin therapy is that these
remarkably effective agents are “2 fers” that both reduce LDL
and have clinically relevant antiinﬂammatory properties. It is
thusdifﬁcult,ifnotimpossible,toinvokethestatinliteratureto
promoteahypothesisofatherothrombosisbasedsolelyonLDL
lowering or on inﬂammation inhibition. Evidence that statins
signiﬁcantly reduce deep vein thrombosis and pulmonary em-
bolism has made this point clear for the clinical community;
there are no atherosclerotic lesions within the venous system
and LDL cholesterol is at best a marginal player in the devel-
opment of venous thrombosis, yet in the JUPITER trial, random
allocation to rosuvastatin as compared with placebo reduced
venous thromboembolism at least as much as it reduced my-
ocardial infarction and stroke.10
In 2010, 2 important papers were published that provided
a further glimpse of how the “lipid” and “inﬂammation” hy-
potheses may be more directly linked than previously appreci-
ated. Each of the 2010 papers reported that the intracellular
NLRP3 inﬂammasome critical for caspase activation and the
subsequent production and secretion of mature interleukin-
1β respond not only to crystalline uric acid and crystalline
pyrophosphate, but also to crystalline cholesterol.11,12 These
observations identify the very early deposition of minimally
modiﬁed LDL cholesterol as an “endogenous danger signal”
capable of triggering interleukin-1β and thus describe a new
pathway by which cholesterol can directly induce a proinﬂam-
matory response. In addition to providing linkage between
LDL cholesterol and early inﬂammation, the NLRP3 data are
clinically relevant as interleukin-1β itself is a driver of the
acute phase response. Thus, cholesterol-driven induction of
the NLRP3 inﬂammasome provides a unifying causal pathway
that helps to explain, in part, why systemic biomarkers of in-
ﬂammation including CRP and interleukin-6 are elevated so
many years in advance of acute coronary obstruction.
In this inaugural issue of the Journal of the American Heart
Association, Ammirati and colleagues in Milan add importantly
to this body of work by presenting data indicating that our un-
derstanding of the complex intersection between lipid biology
and inﬂammation may also require careful cellular subphe-
notyping, at least as we look toward novel T-cell targets for
intervention.13 Previous work from several laboratories has
suggested a role for CD4+ T cells in atherosclerotic lesion
formation, but it has been uncertain as to whether speciﬁc
CD4+ T-cell subsets might have greater or lesser relevance to
disease progression.
Taking advantage of polychromatic ﬂow cytometry (which
allows the simultaneous identiﬁcation of multiple T-cell sub-
phenotypes based on the expression of speciﬁc mark-
ers including CD3/CD4/CD45RO/CD45RA/CCR7/CCR5/
CXCR3/HLA-DR), Ammirati and colleagues show that several
speciﬁc CD4+ subphenotypes of circulating effector mem-
ory T cells (TEM) are preferentially associated with human
atherosclerosis. Speciﬁcally, in one human cohort of stable
patients, the investigators present data that TEM designated
as CD3+CD4+CD45RA−CD45RO+CCR7− were more likely to
associate with common carotid intimal medial thickness and
were more likely to correlate with LDL cholesterol levels than
wereotherT-cellsubphenotypes.Inasecondcohort,theinves-
tigators observed that TEM identiﬁed as HLA-DR+ were more
prevalent among those with chronic stable angina or acute
infarction than among controls free of ischemia. Finally, in a
separate set of mouse studies, the investigators report that
TEM identiﬁed as CD4+CD44+CD62L− are increased in LDL-
receptor and apolipoprotein-E deﬁcient mice and correlate to
a greater extent with aortic root lesions.
The data from Ammirati and colleagues raise intriguing is-
sues about the complex roles played by circulating T-cell sub-
sets in human atherosclerosis, and provide evidence that cel-
lular subphenotyping to identify speciﬁc CD4+ cells that have
lostCCR7mayberelevantasnewtargetsforantiinﬂammatory
therapy are developed. It is also worth considering how these
new observations ﬁt into a uniﬁed hypothesis of cholesterol as
apotentialinstigatingfactorforinﬂammationandearlyathero-
genesis. In hypercholesterolemic animal models, the CCR7
knockout is known to attenuate plaque development.14 Thus,
as memory T cells are broadly antigen-experienced and as
TEM-cell subsets have lost CCR7 receptors, one attractive in-
terpretation of the current data is that cholesterol itself may
be a key antigen stimulating TEM-cell expansion. If so, then the
current data further suggest that a false distinction is being
made in the clinical and investigative communities between
hyperlipidemia and inﬂammation as separate competing pro-
cesses.
A fundamental challenge for any investigative ﬁeld where
entrenched hypotheses dominate care is to ensure that novel
avenues of investigation remain open and productive. Today
within the cardiovascular community, we are blessed to have
major clinical trials underway that are speciﬁcally addressing
whether aggressive LDL cholesterol lowering through path-
ways other than 3-hydroxy-3-methylglutaryl-coenzyme A re-
duction can reduce vascular risk; that are speciﬁcally address-
ingwhetherhigh-densitylipoproteinraisingthroughcholesteryl
ester transfer protein inhibition with or without concomitant
LDL reduction might provide clinical beneﬁt; and that address
whether targeted inhibition of the secretory phospholipases
Lp-PLA2 and sp-LA2 might improve patient outcomes. Re-
cently, my colleagues and I have been given the opportunity to
launch 2 “Cardiovascular Inﬂammation Reduction Trials,” one
funded by industry addressing whether canakinumab (a mono-
clonalantibodytargetinginterleukin-1β)canreducesecondary
event rates, and one funded by the National Heart, Lung and
Blood Institute addressing whether low-dose methotrexate (a
staple for the treatment of rheumatoid arthritis) might also
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confer cardiovascular protection. Strategies being leveraged
by other investigative groups include evaluation of alterna-
tive cytokine and leukotriene inhibitors; methods to directly
prevent monocyte chemotaxis; methods to inhibit mast cell
function; methods to target cell proliferation, adhesion, and
migration; and novel vaccine approaches with the potential
to impact on antigen response and humoral immunity. All of
these novel concepts deserve the support of the clinical car-
diovascular community to ensure adequate patient enrollment
to address fundamental hypotheses. At a minimum, trials of
these agents will enhance our understanding of the intersec-
tion between lipid biology and inﬂammation. If we are lucky,
and if the core biology holds up, one or more of these strate-
gies may ultimately provide substantive clinical beneﬁt for our
patients.
Fifteen years ago, Professor Attilio Maseri—a pioneer in
inﬂammation biology—wrote a commentary on an early CRP
paper15 in which he suggested that observing a relationship
between inﬂammatory biomarkers in currently healthy men
and the risk of future myocardial infarction provided a glimpse
of the “hidden side of the moon.”16 It is thus entirely ﬁtting in
thisinauguralissueoftheJournaloftheAmericanHeartAssoci-
ationthatwecelebratetheongoinginsightsandcreativityfrom
Dr Maseri and his many productive Italian colleagues through
publication of original data that continue to challenge conven-
tional wisdom regarding the linkage between cellular inﬂam-
mation, LDL cholesterol, and clinically evident atherosclerotic
disease. That so many clinical cardiologists worldwide are now
aggressively engaged in trials of novel lipid altering and in-
ﬂammation inhibiting agents is a testament to the distance
bridged by the vascular biology and lipid communities over
these intervening years.
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